Back to Top

Information For Authors

Submit Your Manuscript

STEM CELLS AND DEVELOPMENT welcomes papers covering widely diverse aspects of hematology, bone marrow transplantation, immune reconstitution, and progenitor cell biochemistry and characterization.

Mary Ann Liebert, Inc. Submission Benefits Package

Your submission to Stem Cells and Development provides you with robust tools and support to ensure maximum impact and readership for your work. By submitting your manuscript, you’ll receive:

  • Rapid, rigorous peer-review and editorial attention
  • Immediate deposit to PubMed and other indexing services upon online publication
  • Exposure to thousands of thought-leaders in your field, maximizing readers, citations, and downloads
  • Fast Track online-ahead-of-print publication
  • Global availability in over 170 countries
  • Open Access publication options


All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

Submitting your manuscript to Stem Cells and Development  delivers a comprehensive benefits program that ensures high-quality review of your research and maximum impact for your work. Stem Cells and Development carries a manuscript processing charge* of $75 USD upon submission of each new manuscript.

Upon payment, you will be provided a Manuscript Submission Code, and will be prompted to enter this information when uploading your files to our peer-review system.  Please note:  Securing a token does not automatically create an account in our peer-review system. If you do not already have an account, you will be asked to create one before you can begin your submission.

Submissions do not need to be completed at once. Submitting authors/agents may begin the submission process, save their work, and return to the site to complete the upload(s) at a later time. There is no limit on the number of times one can save their work and subsequently resume the submission. Doing so will not incur additional charges.

Click here to submit your paper via our fast and user-friendly electronic submission system.


Processing charges and submission codes are NOT required for revisions to previously submitted papers. To upload a revision of a paper, the submitting author should log in to their Author Center at click on “Revised Manuscripts in Draft.” The paper will appear in this area, and the submitting author will be able to upload revised files without paying any charges or entering a submission code.

Please be sure to follow the Instructions for Authors below on Manuscript Preparation.  Authors whose submissions do not comply with the Instructions for Authors will have their papers un-submitted so that the file(s) may be adjusted accordingly. Directions regarding the necessary corrective actions will be provided in an email to the corresponding author at the time the paper is un-submitted. The submitting author/agent will then be provided the opportunity to re-upload the corrected file(s). If a paper is un-submitted, the paper will reside in the corresponding author’s “Author Center” as a draft, and the submitting author/agent will be able to make the necessary adjustments and re-upload the paper without incurring another manuscript processing charge. 

*The manuscript processing charge is independent of editorial decision and is non-refundable.


Changes in authorship are not permitted after the acceptance of a paper.


STEM CELLS AND DEVELOPMENT is particularly committed to providing authors comprehensive yet rapid evaluation of original reports describing developments in stem and progenitor cell processing, purging, identification, expansion, biochemistry, molecular biology, and engraftment. Reports describing the results of basic research, technical advances, and clinical studies are within the scope of STEM CELLS AND DEVELOPMENT.  STEM CELLS AND DEVELOPMENT will publish the following types of contributed papers:

Comprehensive Reviews are appraisals of research and clinical trials in fields of current interest. While these are subject to the same review process as other papers, authors are encouraged to speculate about future therapeutic promise of new procedures and techniques. Unsolicited reviews are welcome. Authors of review papers should consult with the Editor-in-Chief about the content and scope of an envisioned review prior to submission of their manuscript.

Cutting Edge Communications are brief, original reports of significant advances that merit accelerated processing and publication. Authors should submit their papers to the Editor-in-Chief, along with a letter outlining the reasons that the work is thought to fall within this category. If the editor agrees that the manuscript potentially provides valuable new information that clearly merits rapid dissemination, processing will be expedited. Otherwise, the manuscript will be processed as a regular submission.

Original Research Reports are full-length descriptions of original research in all fields of stem cell therapy and progenitor cell biology. The investigation may focus on basic science, clinical outcomes, or applications of cell therapy, processing, and transplantation. Processing of these papers will be expedited, and every effort will be made to provide fast turnaround times and to avoid undue delays in the reviewing process.

Technology Reports briefly and succinctly describe improvements or helpful modifications in procedures used for processing, purging,characterizing, and culturing stem cells and progenitors, and other tissues of interest.

Letters to the Editor: Letters to the Editor(s) are welcomed, but with a 500 word limit and no more than one (1) table OR figure, and with a maximum of four (4) references.  

Liebert Instant Online (LION)

To enable the release of new scientific findings as quickly as possible, the Journal has adopted a policy of pre-publishing all manuscripts in unedited format upon acceptance. The papers will have undergone full peer review but will not have been copyedited, typeset, or proofread by the authors. All accepted papers will  appear online as a part of Liebert Instant Online (LION).


On acceptance for publication, the system will generate automatically the author list using the information as submitted to Manuscript Central under 'Authors and Institutions," not as listed in the manuscript file.  It is therefore important to submit correctly the names and email addresses of all authors under 'my authors.' This author list is what will be used for Stem Cells and Development Instant Online and its initial listing on PubMed. Errors at this stage will not be altered, but authors will be able to make corrections at the page proofs stage.


Following its appearance on LION, the paper will progress through the normal publishing process, including author correction of galley proofs.


Manuscripts submitted to STEM CELLS AND DEVELOPMENT will not be rejected solely on the basis of errors in sentence construction, syntax, and grammar. STEM CELLS AND DEVELOPMENT strives to communicate meritorious research from all countries, and reviews will not be compromised due to deficiencies in presentations. However, manuscripts which require substantial editing may, at the authors’ discretion, be referred to an editorial service for a nominal fee. Please contact the Editor-in-Chief for details.


Authors are encouraged to supply the names, addresses, and fax numbers of 3–4 individuals who are considered qualified to review the submitted material, as well as the names of individuals whom the authors would prefer not be included in the review process along with the reason for this request.  Authors may also request that their manuscripts be directed to specific members of the Editorial Board.


WORD LIMITS: Papers should be written succinctly, containing sufficient detail to properly communicate the work and its significance.

All manuscripts will be processed through plagiarism detection software. Plagiarized manuscripts will be rejected.


Manuscripts must be double-spaced in an 8 1/2 x 11 format  with margins of 2.5 cm on each side, and ample space on top and bottom and prepared in Microsoft Word, PC or Macintosh formats.  Please identify the title and authors of the manuscript, its major contribution, suggested reviewers, and other factors as discussed previously.

Please follow these guidelines for submitting figures:

• Do NOT embed art files into a Word or PDF document
• Line illustrations should be submitted at  900 dpi
• Halftones and color should be submitted at a minimum of 300 dpi
• Save as either TIFF or EPS files
• Color art must be saved as CYMK - not RGB
• Black and White art must be submitted as grayscale – not RGB
• PowerPoint or Excel files cannot be uploaded

Please name your artwork files with the submitting authors name e.g. SmithFig1.tif, SmithTable2.tif etc.

You will be given directions on how to correct any files which do not pass.

For submissions containing Western blot images, the original uncropped gels from which the blots were derived must be uploaded as supplemental material under the manuscript category “Original Whole Gel(s) for Western Blots.”  These files will be used for peer review purposes only.


Converting Word or Excel files:  Perhaps the best and easiest way to convert Word or Excel files into a format which is suitable for print is to scan them using the below guidelines:

• All files should be scanned at 100% size
• 300 dpi
• Final color mode: cmyk
• Save file as: .tif or .eps
If you need directions on how to convert a Power Point slide to acceptable format go to


Color Reproduction:  The Journal encourages the submission of color figures, but the cost for color printing must be subsidized by the author(s). These charges, which apply to both unsolicited and invited manuscripts, are necessary to keep the subscription price of Stem Cells and Development

at its current, reasonable rate, and can only be modified by prior consent of the publisher. Please contact the publisher for current rates.


Please supply the following:  a) the complete title of the paper; b) the full name, full mailing address, full contact information (telephone, fax, and e-mail address), and affiliations of each author. Please include the address(es) either on the title page of your paper or on a separate sheet; c) a brief running title; d) the corresponding author’s complete contact information including address and working fax number and/or e-mail address.

Footnotes and abbreviations: List information such as prior conference presentation of the submitted material and a list of non-standard abbreviations (approved abbreviations need not be listed).

Abstract: 300 words or less, without the use of subheadings.

Introduction: Describe the background leading to the study and clearly state the purpose of the study or its major contribution.

Materials and Methods:  Provide sufficient information to permit both reproduction of the results by other investigators and appropriate critical evaluation of the procedures used.  For human research, authors must ensure that studies are performed according to the amended Declaration of Helsinki. Authors should indicate institutional review board approval of the protocol used. Include a statement confirming that all patients gave written informed consent. Where applicable, statement must also be made of approval for human pluripotent stem cell use.  Similarly, all animal research must conform to the respective national guidelines and authors should indicate institutional review board approval of the protocol used.


Discussion: The results and discussion sections of short papers may be combined for more effective presentation.

Acknowledgments: State funding sources and other assistance that were necessary for the conduct of the study.

References:  Should be cited in the text and listed numerically at the end of the paper in the order of citation, as detailed in instructions below.

Figure legends: These must be double-spaced in a separate word file uploaded after the main document.

Tables: Number these consecutively throughout the text.


Disclosure Statement
Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at for further guidance.



Please upload individual files of all manuscript material — do NOT upload a single PDF file containing all text, figure, and table files of your paper.  Once all individual files are uploaded on to Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.


If no conflicts exist, the authors must state “No competing financial interests exist."



References may be made to published work and papers in press. Reference citations are not permitted in the abstract of a paper.  Authors are responsible for the accuracy of all literature citations.  Work in progress, in preparation, unpublished work, and personal communications should be cited as footnotes to the text.  References should be listed numerically in the text in the order of appearance as parenthesized consecutive numbers, e.g., [1,2]. Where there are more than two references, the citation should appear as hyphenated numbers, e.g., [1–3]. References should be typed double-spaced in numerical order of citation, with all authors listed.  Abbreviations of journals should conform to those used in  Medline. The following formats must be used:  


Journal papers

1.  Buckner CD, RB Epstein, RH Rudolph, RA Clift, R Storb and ED Thomas. (1970). Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia. Blood 35:741–750.
2.  Shadduck RK, A Warheed, F Boegel, G Pigoli, A Porcellini and V Rizzoli. (1987). The effect of colony stimulating factor-1 in vivo. Blood Cells 13:49–63.
3.  Wang XS, MC Yoder, SZ Zhou and A Srivastava. (1995). Parvovirus B19 promoter at map unit 6 confers autonomous replication competence and erythroid specificity to adeno-associated virus 2 in primary human hematopoietic pro-genitor cells. Proc Natl Acad Sci (USA) 92:12416–12420.


1.  Gee AP, ed. Bone Marrow Purging and Processing: A Practical Guide. (1991). CRC Press, Boca Raton, FL.

Book chapter

1.  Hénon P. (1993). Clinical aspects of autologous blood stem cell transplantation. Review of indications. In: Peripheral Blood Stem Cell Autografts. E Wunder and P Henon, eds. Springer-Verlag, Heidelberg, pp 209–240.


Written permission must be obtained from the publisher of the journal or book concerned for the reproduction of figures, tables, etc. from copyrighted materials.

The publication from which the figure or table is taken must be listed in the reference list.

A footnote of a reprinted table, or of the legend of a reprinted figure, should read, “Reprinted with permission from Jones et al.” and list the appropriate reference.


Unless rejected for publication, all submissions become the property of Mary Ann Liebert, Inc., Publishers. By submitting their work for review by STEM CELLS AND DEVELOPMENT, all authors and co-authors acknowledge transfer of the copyright of their submission to Mary Ann Liebert, Inc. Such copyright shall automatically revert to the author(s) if the paper is withdrawn prior to the time when the paper is typeset for publication or if the paper is not accepted for publication. While no part of any publication may be reproduced in any form without written consent of the publisher and credit to the original material, such consent shall not unreasonably be denied. Consent can be obtained by contacting the editor-in-chief.


Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.


STEM CELLS AND DEVELOPMENT is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215.  Telephone: (914) 740–2100; fax: (914) 740–2101.

Our dynamic Author Benefits Program provides you with end-to-end benefits that ensure your hard work pays off and your published manuscript gets the attention it deserves not just upon publication, but permanently.

Liebert Open Access

Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option

Explore Liebert Open Access

Does your research funder have an open access mandate or would you like to expand the dissemination of your research?

The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.

The benefits of Liebert Open Access include:

  • High visibility; open access articles are freely available online upon publication
  • You retain copyright with the open access license allowing broad dissemination of your research
  • You can freely share your article in repositories and research networks without restrictions
  • Easy compliance with open access mandates
  • Rigorous editorial and peer-review
  • Targeted email announcement featuring a direct link to article

Identification and Marketing

Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.

Copyright and Licensing

If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

At this time we allow authors to choose between the CC-BY or CC-BY-NonCommercial license. A limited number of journals offer NonCommercial licenses exclusively.

Ordering Open Access

Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email

Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form.  You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.

Publishing biomedical or biotechnology research?

Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.

 *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.


Browse journals in the Liebert Open Access portfolio:

NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

Publishing in Subscription Journals

By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.

Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.

The final published article (version of record) can never be archived in a repository, preprint server, or research network.


Publishing Open Access

Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email or visit Liebert Open Access for more information.

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Upcoming Events

Dec 05 - Dec 09, 2020